Mode
Text Size
Log in / Sign up

Dementia with Lewy bodies

Part of Dementia

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for dementia with Lewy bodies

18 trials tracked for dementia with Lewy bodies: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 1 citation.

18Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 3 Phase 2 8 Other / NA 7
  1. Phase 4 Monitoring Anti-Dementia Drugs by Serum Levels Completed · 1 cited
  2. Phase 4 Anti-Diabetic Medications to Fight PD and LBD Completed
  3. Phase 4 "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" Completed
  4. Phase 2 A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) Completed
  5. Phase 2 Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia Completed
  6. Phase 2 Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies Completed
Show 12 more trials
  1. Phase 2 Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies Completed
  2. Phase 2 Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD) Completed
  3. Phase 2 Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study Completed
  4. Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies Completed
  5. Phase 2 Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies Completed
  6. N/A Palliative Care for Persons With Late-stage Alzheimer's and Related Dementias and Their Caregivers Completed
  7. N/A In-Home Care for Patients With PSP and Related Disorders Completed
  8. N/A Cognitive Stimulation Therapy for Dementia: A Two-Armed Pragmatic Trial Completed
  9. N/A Movement and Music Intervention for Individuals With Dementia Completed
  10. N/A Learning to PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia Completed
  11. N/A Innovations in Dementia Empowerment and Action Completed
  12. N/A Dementia With Lewy Bodies - Infinitome Completed

Showing the 18 most-cited and recently-updated of 18 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Dementia with Lewy bodies: what the trials found

Sitagliptin has been shown to significantly improve outcomes in movement disorders, specifically demonstrating a significant reduction in MDS-UPDRS scores (p=0.008) 1. Armodafinil was found to significantly reduce mean initial sleep latency as measured by the Maintenance of Wakefulness Test (p=0.003) 6.

Other interventions, including Donepezil, showed no significant changes in Clinical Global Impression scores, Geriatric Depression Scale symptoms, or Disability Assessment for Dementia scores 5. RVT-101 35 mg did not result in statistically significant improvements in gait speed (p=0.3565) 11 or in UPDRS-III, ADAS-Cog-11, or CIBIC+ measures 12.

Recent results — preliminary, needs further review

  • * The ADRD-PC Program significantly reduced the number of symptom treatments required by patients (p<0.001) 13. * Referral for Cognitive Stimulation Therapy was associated with a statistically significant reduction in cognitive impairment scores (p=<0.05) 4. * Sitagliptin showed no significant impact on MMSE scores, fasting glucose levels, or other metabolic markers 1.

For the clinician treating this condition

  • Sitagliptin is effective for improving movement disorder scores (MDS-UPDRS), while Armodafinil is effective for reducing sleep latency.
  • The ADRD-PC Program significantly reduces the frequency of required symptom treatments.
  • Cognitive Stimulation Therapy referral is associated with improvements in cognitive impairment scores.

AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Dementia

Related studies from across the Dementia family.

Higher GrimAge epigenetic age acceleration is significantly associated with higher dementia risk
Neurology Meta-analysis
Higher GrimAge epigenetic age acceleration is significantly associated with higher dementia risk GrimAge metric shows link to increased risk of dementia
This meta-analysis of 46,365 individuals with neurodegenerative diseases found that only the GrimAge metric showed a significant association…
One specific biological age clock, known as GrimAge, showed a link to higher dementia risk in a large study of over 46,000 people.
Social isolation and loneliness are significant determinants of cognitive decline and dementia risk in older adults
Psychiatry Sys. Review
Social isolation and loneliness are significant determinants of cognitive decline and dementia risk in older adults Social isolation and loneliness increase risk of dementia in older adults
This systematic review examines the impact of social isolation and loneliness on cognitive decline and dementia risk in older adults. The au…
Loneliness and social isolation are linked to faster cognitive decline and a higher risk of dementia in older adults.
Chronic pain is associated with poorer executive functioning and processing speed in dementia patients
Anesthesiology & Pain Medicine Sys. Review
Chronic pain is associated with poorer executive functioning and processing speed in dementia patients Chronic pain is linked to poorer thinking in people with dementia
This systematic scoping review explores the relationship between chronic pain and cognitive performance in individuals with dementia. The re…
Living with chronic pain may make it harder for people with dementia to manage tasks and process information quickly.
HMB and vitamin D enriched protein supplements may support muscle and cognitive health in dementia
Geriatrics & Aging Sys. Review
HMB and vitamin D enriched protein supplements may support muscle and cognitive health in dementia Nutrition Drink May Help Muscles In Dementia Patients
This narrative review examines the role of high protein oral nutritional supplements enriched with HMB and vitamin D for older adults at ris…
A high protein drink with HMB and vitamin D may support muscle health in older adults with dementia, but brain benefits remain unproven.
HMGB1 acts as a progression-associated inflammatory amplifier in Alzheimer's, Parkinson's, and ALS models
Neurology Sys. Review
HMGB1 acts as a progression-associated inflammatory amplifier in Alzheimer's, Parkinson's, and ALS models New research explores a protein linked to several brain diseases
This narrative review explores the role of HMGB1 in various neurodegenerative diseases including Alzheimer's, Parkinson's, and ALS. The auth…
A specific protein called HMGB1 may act as a driver of inflammation in conditions like Alzheimer's and Parkinson's disease.
Mesenchymal stromal cells and MSC-derived extracellular vesicles may reprogram neuroimmune responses in neurodegenerative diseases
Hematology Sys. Review
Mesenchymal stromal cells and MSC-derived extracellular vesicles may reprogram neuroimmune responses in neurodegenerative diseases Stem cells and vesicles show potential for neurodegenerative diseases
This critical review examines the mechanisms and translational barriers of mesenchymal stromal cells (MSCs) and MSC-derived extracellular ve…
New research explores how stem cell products might protect the brain and repair blood-brain barriers in diseases like Parkinson's and Alzhei…
HRSN assessment tools lack sufficient psychometric testing and reliability data for geriatric populations
Neurology Meta-analysis
HRSN assessment tools lack sufficient psychometric testing and reliability data for geriatric populations New Review Highlights Gaps in Alzheimer's and Dementia Care Tools
This systematic review of 7 studies evaluated the methodological rigor and psychometric properties of HRSN assessment tools in older adults.…
Current tools used to measure social needs for seniors with dementia lack enough testing to ensure they are accurate for older adults.
Scoping review protocol to map living arrangement and carer variables in dementia help-seeking research
Primary Care & Family Medicine Sys. Review
Scoping review protocol to map living arrangement and carer variables in dementia help-seeking research Mapping How Living Arrangements Affect Help Seeking for Dementia
This is a scoping review protocol, not a completed study, that will map how living arrangement and supporter or carer related variables are …
New research plans to map how living situations and family support impact how people with memory problems seek a diagnosis for dementia.
Impact of Receptor Stimulating Antihypertensive Medications on Alzheimer Disease Risk in Elderly Patients
Neurology RCT
Impact of Receptor Stimulating Antihypertensive Medications on Alzheimer Disease Risk in Elderly Patients Certain blood pressure medications may link to lower dementia risk
Retrospective analysis suggests receptor-stimulating antihypertensives may correlate with lower ADRD incidence compared to receptor-inhibiti…
A large study of over 1.5 million seniors suggests specific blood pressure medications may be linked to lower rates of dementia and cognitiv…
Comprehensive dementia care interventions improve caregiver self-efficacy in those with lower baseline scores
Physical Medicine & Rehab RCT
Comprehensive dementia care interventions improve caregiver self-efficacy in those with lower baseline scores Comprehensive Care Programs May Improve Confidence for Dementia Caregivers
This secondary analysis of a randomized pragmatic clinical trial involved 2037 caregivers of community-dwelling persons living with dementia…
Caregivers of people with dementia can improve their self-efficacy and confidence through comprehensive care programs.
Non-pharmacological interventions for sleep disturbances in mild cognitive impairment and early dementia provide management guidance
Palliative Care Guideline
Non-pharmacological interventions for sleep disturbances in mild cognitive impairment and early dementia provide management guidance Sleep Care Plan for Early Dementia: Best Evidence
This integrative review and guideline identifies 44 evidence items across 11 themes for managing sleep disturbances in patients with mild co…
A new review maps 44 best evidence items for managing sleep problems in mild cognitive impairment and early dementia.
Impact of Domain Specific Physical Activity on Risk of All Cause Dementia
Neurology Meta-analysis
Impact of Domain Specific Physical Activity on Risk of All Cause Dementia High levels of physical activity linked to lower dementia risk
A massive meta-analysis of over 4 million participants reveals that specific types of physical activity significantly influence dementia ris…
Active lifestyles, especially during leisure time, are linked to a lower risk of developing Alzheimer's and other forms of dementia.

Questions about dementia with Lewy bodies

Do people with iRBD biomarkers have more cognitive symptoms than healthy controls?

People with iRBD biomarkers show worse cognitive performance than healthy controls, with higher rates of mild cognitive impairment and neuropsychiatric symptoms.

Full answer →
Can DATSCAN imaging help diagnose dementia with Lewy bodies?

Yes, DATSCAN imaging helps diagnose dementia with Lewy bodies by showing reduced dopamine transport in the brain, which supports the diagnosis when other symptoms are unclear.

Full answer →